Quality Comes First

COUNTRIES

CONTACT US

Our Pipeline and Products

Menarini is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by serious conditions.

Read more

MENARINI is a fully integrated privately owned pharma company with a long and successful heritage in strategic partnering across the globe. We have a profound know-how stemming from our strong R&D capabilities in key therapeutic areas, coupled with our excellence in commercial execution and our powerful direct presence on a global basis.

Share your partnering idea

Our dedicated Corporate Business Development team is committed to assess and explore innovative new opportunities.

 

Contact Us

Donations of backpacks and cases for school, distribution of meals and medicines, promotion of sport, support for pregnant women and much more: being responsible for Menarini means transforming good intentions into concrete efforts. By helping others, we want to contribute to improve the world around us, starting with us.

Our Values

Everyday we put our values into action. 4 values, which have given life to Menarini and shaped its history.

 

Read more

What does it really make Menarini unique? The diversity and authenticity of our key resource - the People.
Our cultural diversity helps us to drive innovation, adapt to business changes, face challenges, inspire ideas and develop our growth.

Available positions on Linkedin

Menarini employees make all the difference, every day.

 

Follow Us On Linkedin

News

2024-12-05

A. Menarini Diagnostics and Sinocare Announce Exclusive Distribution Agreement for New Continuous Glucose Monitoring System

 

Florence, Italy - 3rd December 2024.  A. Menarini Diagnostics announces an exclusive Distribution Agreement with Sinocare to register, promote, distribute, and market a new Sinocare 3rd Generation Continuous Glucose Monitoring (CGM) System within reimbursed markets. This landmark agreement grants A. Menarini Diagnostics exclusive rights to introduce this health technology to more than 20 jurisdictions in Europe.

The collaboration between A. Menarini Diagnostics and Sinocare represents a significant advancement in diabetes care. Sinocare's  CGM system technology provides accurate and continuous glucose monitoring.

"The partnership with A. Menarini Diagnostics is a significant milestone in our mission to make our 3rd Generation CGM Systems widely accessible to people with diabetes," stated Dr. Jiangfeng Fei, Head of CGM Business Unit, Sinocare. "We are pleased to enter into a strategic partnership with A. Menarini Diagnostics, a leader in the healthcare industry, to bring this innovative diabetes technology to a broader audience."

A. Menarini Diagnostics shares this enthusiasm for the collaboration and its potential impact on diabetes care. "Securing exclusive rights for the distribution and marketing of this Sinocare 3rd Generation CGM System across various countries aligns with our commitment to providing innovative healthcare solutions," commented Fabio Piazzalunga, General Manager and Global Head of A. Menarini Diagnostics. "We are confident that this long-term partnership will meet the growing demand for advanced diabetes care."

By leveraging its extensive network, expertise, and resources, A. Menarini Diagnostics aims to ensure that Sinocare 3rd Generation CGM Systems reach those who can benefit most from its advanced capabilities. This partnership is expected to significantly expand the availability of Sinocare’s 3rd Generation CGM systems. 

About A. Menarini Diagnostics
A. Menarini Diagnostics is a leading healthcare company dedicated to providing innovative solutions for better health outcomes through advanced diagnostic tools and technologies. The company has more than 45 years dedicated to helping healthcare professionals make safe and sustainable diagnosis, improving the quality of life of people all over the world. A. Menarini Diagnostics is part of the Menarini Pharmaceutical Group, founded in 1886. Today it is present in 140 countries throughout the world, with more than 17,000 employees and 2023 turnover of € 4.375 billion.

About Sinocare
Sinocare is the largest manufacturer of glucose monitoring devices in Asia. Founded in 2002, Sinocare Inc., was the first blood glucose meter company to be listed in China. With a commercial presence in Asia, Europe and North America Sinocare has expanded internationally through partnerships and acquisitions such as the USA based PTS Diagnostics Inc., Nipro Diagnostic Inc., now known as Trividia Health Inc. 
Our dedication to innovation in biosensing technology has helped Sinocare become the global 4th largest blood glucose meter manufacturer and one of the leading POCT companies worldwide.


For media enquiries:Menarini Group, pressoffice@menarini.com  +39 055 56801

For marketing enquiries: internationaldiagnostics@menarini.it

Sinocare contact details: PBDDept@sinocare.com 

Follow Us

A.Menarini Industrie Farmaceutiche Riunite S.r.l.

VAT number and registration number in the Company House: 00395270481
Office of the Companies House: Florence
Share Capital: € 150.000.0000 I.V.

 

© 2025 The Menarini Group - All rights reserved

Fraud Warning Disclaimer

Please be aware that certain individuals might approach you by falsely presenting themselves as our employees, affiliates, agents or representatives. Under this false pretense, they might try to gain access to your personal information or to acquire money or other valuables from you by offering fictitious employment opportunities or by claiming that they are contacting you on our behalf. The contacting individual or organisation may, for example, claim that we can guarantee your employment if you pay them a certain amount of money. Such fraudulent offers and claims are usually received via email, the internet, text message, phone, etc. These claims and offers are fraudulent and invalid and you are strongly advised to exercise great caution when you receive such an offer of employment or notice. Be very mindful of such scams.Below we list some of the features such an offer or claim may have:

Below we list some of the features such an offer or claim may have:

• It may propose a phone or instant message program interview and/or money as a precondition for hiring You may be requested to disclose private, sensitive or confidential information

• You may be told that you were contacted in such a manner because it is a matter of urgency

Such an offer or claim will probably be in the form of an email sent from a fake email address or from a free email address and not from an official Menarini Group email address. Please take extra caution while examining such an email address, as the perpetrators may misspell an official Menarini Group email address and use a slightly modified version of an official Menarini Group email address.

Please note that you will never receive a fraudulent employment offer or any other similar claim from us, because we do not provide any recruitment services. Moreover, we will never ask you for money in exchange for employment opportunities or other similar services. Any such offer of employment or any other service in exchange for fees that claims to be from us is deceitful and part of a fraud.

Criminal and/or civil liabilities may arise from such actions and we intend to cooperate with competent law enforcement agencies. Accordingly, we would ask you to immediately get in touch with us upon receiving a suspicious offer or claim and additionally notify the police or other competent authority.

In any case, please disregard any written or oral request related to a job offer or an interview that you believe is or might be fraudulent or suspicious.

Please note that under no circumstances shall Menarini Group be held liable or responsible for any claims, losses, damages, expenses or other inconvenience resulting from or in any way connected to the actions of these imposters.